A Safety Study of LY3372689 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3372689

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04106206

17242

I9X-MC-MTAC (Other Identifier)

Details and patient eligibility

About

This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3372689 or placebo and will remain in the study for up to eight weeks.

Enrollment

54 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly healthy vasectomized male or a female who cannot get pregnant
Have a body mass index (BMI) of 18.5 to ≤30 kilograms per square meter (kg/m²)
Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
Have veins suitable for ease of blood sampling

Exclusion criteria

Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
Have previously participated or withdrawn from this study
Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study